Treatment Options for Patients With Chronic Hepatitis C Not Responding to Initial Antiviral Therapy

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 9, 2009, Pages 921-930

  Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; COLCHICINE; CONSENSUS INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; R 7128; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS RNA;

ADD ON THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; ESOPHAGUS VARICES BLEEDING; EVENT FREE SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; PORTAL HYPERTENSION; RELAPSE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT FAILURE; VIRAL LOAD;

EID: 69249101721     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.03.033     Document Type: Review

References (52)

1. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264
2. World Health Organization. Hepatitis C. World Health Organization, 2000 October. www.who.int/mediacentre/factsheets/fs165/en Accessed April 12, 2006
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
5. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
6. Jacobson I.M., Brown Jr. R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46 (2007) 971-981
7. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 40 (2004) 993-999
8. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
9. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
10. FDA approves an expanded indication for peginterferon-based combination therapy for patients with chronic hepatitis C [press release]. Kenilworth, NJ: Schering-Plough Corporation; March 11, 2009. http://www.schering-plough.com/news/news_article.aspx?reqid=1265325. Accessed July 7, 2009.
11. Cheng S.J., Bonis P.A.L., Lau J., et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 33 (2001) 231-240
12. Camma C., Bruno S., Schepis F., et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut 51 (2002) 864-869
13. Cummings K.J., Lee S.M., West E.S., et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 285 (2001) 193-199
14. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126 (2004) 1015-1023
15. Krawitt E.L., Ashikaga T., Gordon S.R., et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 43 (2005) 243-249
16. Sherman M., Yoshida E.M., Deschenes M., et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55 (2006) 1631-1638
17. Bocher W.O., Schuchmann M., Link R., et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-a therapy. Liver Int 26 (2006) 319-325
18. Cornberg M., Hadem J., Herrmann E., et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 44 (2006) 291-301
19. Jacobson I.M., Gonzalez S.A., Ahmed F., et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 100 (2005) 2453-2462
20. Heathcote E.J.L., Keeffe E.B., Lee S.S., et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 27 (1998) 1136-1143
21. Shiffman M.L., Ghany M.G., Morgan T.R., et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132 (2007) 103-112
22. Moucari R., Ripault M.-P., Oules V., et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 46 (2007) 596-604
23. Basso M., Torre F., Grasso A., et al. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Dis Sci 39 (2007) 47-51
24. Goncales Jr. F.L., Vigani A., Goncales N., et al. Weight-based combination therapy with peginterferon a-2b and ribavirin for naive, relapser and non-responder patients with chronic hepatitis C. Braz J Infect Dis 10 (2006) 311-316
25. Parise E., Cheinquer H., Crespo D., et al. Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 10 (2006) 11-16
26. Taliani G., Gemignani G., Ferrari C., et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 130 (2006) 1098-1106
27. Gross J., Johnson S., Kwo P., et al. Double-dose peginterferon alpha-2b with weight-based ribavirin improves response for interferon/ribavirin nonresponders with hepatitis C: final results of "RENEW.". Hepatology 42 Suppl 1 (2005) 219A
28. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa ribavirin therapy. Gastroenterology 136 (2009) 1618-1628
29. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499
30. Saracco G., Olivero A., Ciancio A., et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 36 (2002) 959-966
31. Jensen D.M., Freilich B., Andreone P., et al. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology 46 Suppl 1 (2007) 291A abstract LB4
32. Jensen D.M., Freilich B., Andreone P., et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon alfa-2b. Ann Int Med 150 (2009) 528-540
33. Rustgi V.K., Esposito S., Hamzeh F.M., et al. Safety and tolerability of peginterferon alpha-2a/ribavirin in HCV patients non-tolerant or nonresponsive to peginterferon alpha-2b/ribavirin. Gastroenterology 132 Suppl S1 (2007) A-794 abstract M1872
34. Kaiser S., Hass H., and Gregor M. Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy. Hepatology 40 Suppl 1 (2004) 240A abstract 173
35. Leevy C.B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci 53 (2008) 1961-1966
36. Kaiser S., Hass H., Lutze B., et al. Comparison of daily consensus interferon versus peginterferon alfa 2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C. Gastroenterology 130 Suppl 2 (2006) A-784 abstract S1060
37. Bacon B.R., Shiffman M.L., Mendes F., et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49 (2009) 1838-1846
38. Marcellin P., Freilich B., Andreone P., et al. HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: results from REPEAT study. J Hepatol 48 (2008) S301 abstract 805
39. Marcellin P., Freilich B., Andreone P., et al. Type of response to prior pegylated interferon alfa-2b (12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2a (40KD)/RBV. J Hepatol 48 (2008) S301 abstract 806
40. McHutchison J.G., Bartenschlager R., Patel K., and Pawlotsky J.-M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 44 (2006) 411-421
41. Nelson D.R., Rustgi V., Balan V., et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 7 (2009) 212-218
42. Nelson D., Rustgi V., Balan V., et al. Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: interim results from a phase 2 study. Hepatology 44 Suppl 1 (2006) 611A abstract 1136
43. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
44. Bruix J., Poynard T., Colombo M., et al. Pegintron maintenance therapy in cirrhotic (Metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial. J Hepatology 50 Suppl 1 (2009) S22
45. Afdhal N., Levine R., Brown Jr. R., et al. Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year COPILOT trial. J Hepatol 48 (2008) S4 abstract 3
46. Afdhal N., O'Brien C., Godofsky E., et al. Valopicitabine (NM283), alone or with peginterferon, compared to peginterferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one-year results. J Hepatology 46 Suppl 1 (2007) S5
47. Potential safety issue identified in ongoing phase 2 clinical study of HCV-796. [press release] (2007), PR Newswire-FirstCall, Exton, PA August 10
48. Reddy R., Rodriguez-Torres M., Gane E., et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46 Suppl (2007) 862A-863A abstract LB9
49. Gane E.J., Rodriguez-Torres M., Nelson D.R., et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days. Hepatology 48 Suppl (2008) 1024A abstract LB10
50. Schiff E., Poordad F., Jacobson I., et al. Boceprevir (NS3 protease inhibitor) combination therapy in non responders: phase II dose finding study. J Hepatol 48 (2008) S46 abstract 104
51. McHutchison J.G., Shiffman M.L., Terrault N., et al. A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa-2a/b and ribavirin therapy: PROVE3 interim results. Hepatology 48 Suppl (2008) 431A-432A abstract 269
52. Shiffman M.L., Berg T., Poordad F.F., et al. A study of telaprevir combined with peginterferon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa-2a and ribavirin treatment: interim analysis. Hepatology 48 Suppl (2008) 1135A-1136A abstract 1852